Roche stakes $2bn on UCB Alzheimer’s disease treatment
Swiss company Roche has partnered with Belgium-based biopharmaceutical company UCB to develop an antibody treatment for people living with Alzheimer’s disease.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
16 July 2026 A Munich court ruled that Illumina infringed a rival’s DNA sequencing patents, handing the challenger an early victory in a dispute that is playing out across Europe and the US.
15 July 2026 French drugmaker's Translate Bio unit accuses COVID rivals of infringing core lipid nanoparticle and mRNA purification patents, seeking damages from vaccines worth billions.
10 July 2026 Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science.
